Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482111 | 0.83 | CHRNA1 (0.50) | TSHRSMN1; SMN2ALDH1A1PARP1APOBEC3A | |
| Hydrochloric Acid SCHEMBL8796442 | 0.82 | CHRNA1 (0.49) | TSHRSMN1; SMN2ALDH1A1PARP1APOBEC3A | |
| SCHEMBL154862 | 0.81 | HPGD (0.58) | HPGDTSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29935432 | 0.81 | HPGD (0.58) | HPGDTSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL407154 | 0.81 | RAB9A (0.67) | HPGDTSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29503140 | 0.80 | PRSS1 (0.61) | HPGDNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL27557037 | 0.80 | PARP1 (0.54) | TSHRSMN1; SMN2ALDH1A1PARP1KMT2A | |
| SCHEMBL1002832 | 0.80 | PRSS1 (0.61) | HPGDNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29477006 | 0.79 | HPGD (0.56) | HPGDTSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1708334 | 0.79 | HPGD (0.56) | HPGDTSHRNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| JP-2007523865-A | — | — | 2007-08-23 | — | — | JP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-7129235-B2 | Amides useful for treating pain | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | claimed |
| EP-1646621-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2006-04-19 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | ABBVIE INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005007642-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2005-01-27 | — | — | WO | claimed |
| US-20230165251-A1 | SUBSTITUTED TOLYL FUNGICIDES AND THEIR MIXTURES | FMC CORPORATION | 2023-06-01 | — | — | US | disclosed |
| US-20230165251-A1 | SUBSTITUTED TOLYL FUNGICIDES AND THEIR MIXTURES | FMC CORPORATION | 2023-06-01 | — | — | US | disclosed |
| WO-2022066917-A1 | 3-(6-AMINOPYRIDIN-3-YL)BENZAMIDE DERIVATIVES AS RIPK2 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-31 | — | — | WO | disclosed |
| WO-2021226234-A1 | SUBSTITUTED TOLYL FUNGICIDES AND THEIR MIXTURES | FMC CORPORATION (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021038419-A1 | KINASE INHIBITORS AND METHODS OF SYNTHESIS AND TREATMENT | INSILICO MEDICINE IP LIMITED (CN) | 2021-03-04 | — | — | WO | disclosed |
| US-20030144329-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2003-07-31 | — | — | US | disclosed |
| US-20030105333-A1 | RXR activating molecules | MAXIA PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003043998-A1 | N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-05-30 | — | — | WO | disclosed |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003016267-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INCORPORATED (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002072543-A2 | RXR ACTIVATING MOLECULES | MAXIA PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105333-A1 | RXR activating molecules | RXRG, RXRB, RXRA | HPGD 1662/4885TSHR 52/4885NPC1 1657/4885 |
| US-20030144329-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | CYP27A1, CYP46A1, PNLIP | HPGD 335/4885TSHR 1454/4885NPC1 12/4885 |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | OAT, CPT1A, CYP27A1 | HPGD 524/4885TSHR 974/4885NPC1 143/4885 |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | TRPV1, OPRL1, TRPV6 | HPGD 2532/4885TSHR 397/4885NPC1 1062/4885 |
| US-20230165251-A1 | SUBSTITUTED TOLYL FUNGICIDES AND THEIR MIXTURES | NAT1, TH, Q6ZSR9 | HPGD 4405/4885TSHR 918/4885NPC1 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.